The European Commission and German biotech firm CureVac CVAC.O said on Thursday they were in advanced talks for the supply of at least 225 million doses of a potential COVID-19 vaccine to EU states.
The European Union's executive arm is also in talks with Johnson & Johnson and Sanofi for their vaccines under development and agreed last week an advanced purchase deal with AstraZeneca for at least 300 million doses of the shot it is developing with Oxford University.
"Today we concluded talks with...CureVac to increase the chances of finding an effective coronavirus vaccine," EU Health Commissioner Stella Kyriakides said, confirming a Reuters report in July.
The EU will now begin negotiating a contract with CureVac, which could be the company's first bilateral supply deal, aimed at securing the vaccine for all 27 EU member states should the shot prove safe and effective.
EU will now begin negotiating a contract with CureVac
CureVac said on Thursday the talks included an option to supply 180 million additional doses. The company's shares soared as much as 222% after its Nasdaq debut on Friday, the first by a company developing a COVID-19 vaccine.
EU officials told Reuters last month that the Commission was also in talks with U.S. biotech firm Moderna and German firm BioNtech, which is developing a vaccine with U.S. pharmaceutical company Pfizer.
CureVac's approach is based on so-called messenger RNA, pieces of genetic code that prompt human cells to produce therapeutic proteins. Moderna and BionTech are using similar technology.
CureVac said it could start large-scale human trials on its vaccine in the last quarter of this year based on results of its current trials.
The Commission did not disclose financial details but said funding would be provided through an EU emergency fund, of which around 2 billion euros ($2.37 billion) can be used to finance advance purchase deals, officials have told Reuters.
